Cat.No：GM-87478MAB
Product ：Anti-CDH6 hIgG1 Reference Antibody (Ralubio)
Cat.No：GM-87478MAB
Product ：Anti-CDH6 hIgG1 Reference Antibody (Ralubio)
GM-87478MAB-1mg / 1 mg
GM-87478MAB-5mg / 5 mg
GM-87478MAB-25mg / 25 mg
GM-87478MAB-50mg / 50 mg
GM-87478MAB-100mg / 100mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target CDH6
Clone raludotatug
Alternative Names CAD6; KCAD
Source/Isotype Human IgG1(K214R/D356E/L358M), Kappa
Application /
Description CDH6, also known as K-cadherin, belongs to type II cadherin and is composed of three distinct domains, an extracellular domain (ECD) containing five cadherin sequences, a transmembrane region, and an intracellular tail. CDH6 is highly expressed in many malignant tumors (human renal cell carcinoma, ovarian cancer, thyroid cancer, cholangiocarcinoma, and small cell lung cancer), and overexpression of CDH6 protein has a worse prognosis than cases with low or no CDH6 protein expression. Therefore, it can be used to target CDH6 related small molecule drugs or monoclonal antibodies, double antibodies.
Formulation phosphate-buffered solution, pH 7.4.
Cat.No：GM-87478MAB
Product ：Anti-CDH6 hIgG1 Reference Antibody (Ralubio)
GM-87478MAB-1mg / 1 mg
GM-87478MAB-5mg / 5 mg
GM-87478MAB-25mg / 25 mg
GM-87478MAB-50mg / 50 mg
GM-87478MAB-100mg / 100mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target CDH6
Clone raludotatug
Alternative Names CAD6; KCAD
Source/Isotype Human IgG1(K214R/D356E/L358M), Kappa
Application /
Description CDH6, also known as K-cadherin, belongs to type II cadherin and is composed of three distinct domains, an extracellular domain (ECD) containing five cadherin sequences, a transmembrane region, and an intracellular tail. CDH6 is highly expressed in many malignant tumors (human renal cell carcinoma, ovarian cancer, thyroid cancer, cholangiocarcinoma, and small cell lung cancer), and overexpression of CDH6 protein has a worse prognosis than cases with low or no CDH6 protein expression. Therefore, it can be used to target CDH6 related small molecule drugs or monoclonal antibodies, double antibodies.
Formulation phosphate-buffered solution, pH 7.4.
